Assembly Biosciences (ASMB) came out with a quarterly loss of $0.93 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to a loss of $0.72 per share a year ago.
Assembly Biosciences' investment thesis is a high-risk, binary bet on clinical pipeline execution, with its financials dominated by lumpy collaboration revenue rather than sustainable commercial traction.
Price trend, volume and key moving averages
Trailing total returns as of 11/19/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 12, 2026 | -$0.93-42.0% vs -$0.66 | $3M-67.4% vs $9M |
Q3 2026 Aug 13, 2026 | -$0.20+72.4% vs -$0.72 | $13M+55.5% vs $9M |
Q2 2026 May 7, 2026 | -$0.54+26.0% vs -$0.73 | $8M-11.4% vs $9M |
Q2 2026 Mar 19, 2026 | $2.48+586.3% vs -$0.51 | $42M+472.2% vs $7M |
Assembly Biosciences (ASMB) came out with a quarterly loss of $0.93 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to a loss of $0.72 per share a year ago.
– Initiated Phase 2 clinical study of ABI-6250 in patients with chronic hepatitis delta virus infection –

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced senior management will present and participate in one-on-one meetings at the following upcoming investor conferences in November:
– Phase 2 study will evaluate the safety, pharmacokinetics and antiviral activity of ABI-6250 in participants with chronic HDV infection – – Initial data from the Phase 2 study is expected in the fourth quarter of 2027 –
Benchmark ASMB against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Assembly Biosciences, Inc. (ASMB)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $22.50 | $445.89M | -44.14 | 153.52% | -16.57% | -4.4% | — | |
| $42.99 | $6.06B | -8.41 | -45.65% | -160.64% | -172.62% | — | |
| $2.11 | $230.4M | -14.85 | — | — | -5.34% | — | |
| $19.69 | $1.65B | -7.64 | — | — | -157.78% | — | |
| $170.26 | $211.39B | -55.14 | 2.39% | -12.47% | -21.84% | 1.87% | |
| $957.76 | $98.67B | 20.99 | 0.99% | 28.51% | 15.07% | 0.36% |
Assembly Biosciences, Inc. (ASMB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Assembly Biosciences, Inc. (ASMB) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 13, 2026·SEC
Jun 5, 2026·SEC
May 26, 2026·SEC
Get notified when ASMB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Assembly Biosciences, Inc. (ASMB) stock FAQ — growth, dividends, profitability & financials explained
Assembly Biosciences, Inc. (ASMB) reported $67.0M in revenue over the trailing twelve months. Revenue was $72.3M in fiscal year 2025.
Assembly Biosciences, Inc. (ASMB) grew revenue by 80.2% over the trailing twelve months, compared with the twelve months before.
No. Assembly Biosciences, Inc. (ASMB) reported a net loss of $11.1M over the trailing twelve months.
Assembly Biosciences, Inc. (ASMB) had a return on equity (ROE) of -4.4% over the trailing twelve months. A negative ROE means the company lost money over the period.
Assembly Biosciences, Inc. (ASMB) had negative free cash flow of $40.7M over the trailing twelve months.